Corvus Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRVS research report →
Companywww.corvuspharma.com
Corvus Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers.
- CEO
- Richard A. Miller
- IPO
- 2016
- Employees
- 31
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $1.03B
- P/E
- -24.84
- P/S
- 0.00
- P/B
- 4.56
- EV/EBITDA
- -20.79
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -38.92%
- ROIC
- -19.84%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-15,283,000 · 75.47%
- EPS
- $-0.19 · 81.37%
- Op Income
- $-42,971,000
- FCF YoY
- -29.68%
Performance & Tape
- 52W High
- $26.95
- 52W Low
- $3.38
- 50D MA
- $15.00
- 200D MA
- $11.11
- Beta
- 0.94
- Avg Volume
- 1.39M
Get TickerSpark's AI analysis on CRVS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 18, 26 | MILLER RICHARD A MD | buy | 1,932 |
| May 18, 26 | MILLER RICHARD A MD | buy | 5,000 |
| Apr 23, 26 | Chan Andrew C. | other | 30,000 |
| Apr 23, 26 | Chan Andrew C. | other | 0 |
| Jan 28, 26 | Thompson Peter A. | other | 15,000 |
| Jan 28, 26 | Thompson Peter A. | other | 15,000 |
| Jan 28, 26 | Thompson Peter A. | other | 15,000 |
| Jan 28, 26 | Thompson Peter A. | other | 15,000 |
| Jan 28, 26 | Thompson Peter A. | other | 15,000 |
| Jan 28, 26 | Thompson Peter A. | other | 15,000 |
Our CRVS Coverage
We haven't published any research on CRVS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CRVS Report →